Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. Show more

Location: Connaught House, Dublin, D04 C5Y6, Ireland | Website: https://www.alkermes.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare


Market Cap

4.782B

52 Wk Range

$22.90 - $36.45

Previous Close

$29.00

Open

$29.08

Volume

1,122,086

Day Range

$28.68 - $29.22

Enterprise Value

3.908B

Cash

884M

Avg Qtr Burn

N/A

Insider Ownership

1.50%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
LYBALVI (ALKS 3831) Details
Bipolar disease, Mental health, Schizophrenia

Approved

Quarterly sales

Vivitrol (naltrexone) Details
Alcohol dependence, Opioid dependence

Approved

Quarterly sales

Aristada (aripiprazole lauroxil) Details
Mental health, Schizophrenia

Approved

Quarterly sales

Phase 2

Data readout

Phase 2

Data readout

ALKS 2680 (RDC-264177) Details
Idiopathic hypersomnia

Phase 2

Update